JP2020526534A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526534A5 JP2020526534A5 JP2020500862A JP2020500862A JP2020526534A5 JP 2020526534 A5 JP2020526534 A5 JP 2020526534A5 JP 2020500862 A JP2020500862 A JP 2020500862A JP 2020500862 A JP2020500862 A JP 2020500862A JP 2020526534 A5 JP2020526534 A5 JP 2020526534A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- composition according
- multiple myeloma
- activator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530778P | 2017-07-10 | 2017-07-10 | |
| US62/530,778 | 2017-07-10 | ||
| US201762593185P | 2017-11-30 | 2017-11-30 | |
| US62/593,185 | 2017-11-30 | ||
| US201862675581P | 2018-05-23 | 2018-05-23 | |
| US62/675,581 | 2018-05-23 | ||
| PCT/US2018/041230 WO2019014100A1 (en) | 2017-07-10 | 2018-07-09 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526534A JP2020526534A (ja) | 2020-08-31 |
| JP2020526534A5 true JP2020526534A5 (enExample) | 2022-11-02 |
| JP7258009B2 JP7258009B2 (ja) | 2023-04-14 |
Family
ID=63036419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020500862A Active JP7258009B2 (ja) | 2017-07-10 | 2018-07-09 | 抗増殖化合物及びその使用方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US10357489B2 (enExample) |
| EP (3) | EP4467143B1 (enExample) |
| JP (1) | JP7258009B2 (enExample) |
| KR (1) | KR102656934B1 (enExample) |
| CN (1) | CN110869021B (enExample) |
| AU (2) | AU2018301335B2 (enExample) |
| CA (1) | CA3069138A1 (enExample) |
| CL (1) | CL2020000060A1 (enExample) |
| CO (1) | CO2020000193A2 (enExample) |
| DK (1) | DK3651766T3 (enExample) |
| EC (1) | ECSP20001149A (enExample) |
| ES (2) | ES3067922T3 (enExample) |
| FI (1) | FI3651766T3 (enExample) |
| HR (2) | HRP20260520T1 (enExample) |
| HU (1) | HUE069137T2 (enExample) |
| IL (1) | IL271889B2 (enExample) |
| LT (1) | LT3651766T (enExample) |
| MX (1) | MX2023000085A (enExample) |
| PL (1) | PL3651766T3 (enExample) |
| PT (1) | PT3651766T (enExample) |
| RS (2) | RS66162B1 (enExample) |
| SA (1) | SA520411007B1 (enExample) |
| SG (1) | SG11202000143PA (enExample) |
| SI (1) | SI3651766T1 (enExample) |
| SM (2) | SMT202400470T1 (enExample) |
| TW (2) | TWI791552B (enExample) |
| WO (1) | WO2019014100A1 (enExample) |
| ZA (1) | ZA202000157B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| CN118344338A (zh) | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| IL278854B2 (en) | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| PL3796912T3 (pl) * | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| US20210330788A1 (en) * | 2018-07-11 | 2021-10-28 | Celgene Corporation | Uses of anti-bcma chimeric antigen receptors |
| CN113573719A (zh) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | 治疗和t细胞调节的方法和组合 |
| DK3908281T3 (da) * | 2019-01-09 | 2024-10-21 | Celgene Corp | Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom |
| EP3908582B1 (en) * | 2019-01-09 | 2025-11-12 | Celgene Corporation | Solid forms comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and salts thereof, and compositions comprising and methods of using the same |
| AU2020206692B2 (en) * | 2019-01-09 | 2025-03-27 | Celgene Corporation | Pharmaceutical compositions comprising (S)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| AR119715A1 (es) | 2019-04-12 | 2022-01-05 | Celgene Corp | Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona |
| HRP20231487T1 (hr) | 2019-10-21 | 2024-03-01 | Celgene Corporation | Postupci za liječenje hematoloških malignosti uporabom 2-(2,6-dioksopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)benzil)amino)izoindolin-1,3-diona |
| JP7852923B2 (ja) | 2019-11-27 | 2026-04-28 | キャプター セラピューティクス エス．エー． | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
| WO2021105335A1 (en) | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| EP4095132A1 (en) | 2020-01-20 | 2022-11-30 | Kangpu Biopharmaceuticals, Ltd. | Isoindoline derivative, and pharmaceutical composition and use thereof |
| KR20230004493A (ko) * | 2020-04-17 | 2023-01-06 | 에시언트 파마슈티컬스 인코포레이티드 | Mas-관련 G-단백질 수용체 X4의 조절제 및 관련 제품 및 방법 |
| CA3181399A1 (en) * | 2020-04-28 | 2021-11-04 | Juno Therapeutics, Inc. | Combination of bcma-directed t cell therapy and an immunomodulatory compound |
| AU2021263408A1 (en) * | 2020-04-30 | 2022-10-27 | Bristol-Myers Squibb Company | Methods of treating cytokine-related adverse events |
| CN115916191B (zh) | 2020-06-25 | 2026-06-23 | 新基公司 | 用组合疗法治疗癌症的方法 |
| CN113896711A (zh) * | 2020-07-06 | 2022-01-07 | 北京诺诚健华医药科技有限公司 | 杂环类免疫调节剂 |
| ES2988714T3 (es) | 2020-07-07 | 2024-11-21 | Celgene Corp | Composiciones farmacéuticas que comprenden (S)-4-(4-(4-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencilo)piperazin-1-il)-3-fluorobenzonitrilo y métodos de uso de las mismas |
| CN120004860A (zh) * | 2020-07-20 | 2025-05-16 | 江苏恒瑞医药股份有限公司 | 含硫异吲哚啉类衍生物、其制备方法及其在医药上的应用 |
| AU2021319847A1 (en) | 2020-08-03 | 2023-03-02 | Captor Therapeutics S.A. | Low molecular weight protein degraders and their applications |
| WO2022146151A1 (en) | 2020-12-30 | 2022-07-07 | Captor Therapeutics S.A. | Novel compounds which bind to cereblon, and methods of use thereof |
| CN114685429A (zh) * | 2020-12-31 | 2022-07-01 | 江苏恒瑞医药股份有限公司 | 碳链环己二酰亚胺类化合物、其制备方法及其在医药上的应用 |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| KR20240013793A (ko) * | 2021-05-27 | 2024-01-30 | 셀진 코포레이션 | 조합 요법을 사용하는 다발성 골수종의 치료 방법 |
| WO2022255889A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022255890A1 (en) | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| JP2024528988A (ja) | 2021-08-06 | 2024-08-01 | セルジーン コーポレーション | 改変タンパク質の選択的分解のための組成物および方法 |
| CN116023319A (zh) * | 2021-10-25 | 2023-04-28 | 英格尔医药科技(上海)有限公司 | 制备布瓦西坦的方法 |
| CN116462660A (zh) * | 2022-01-19 | 2023-07-21 | 江苏恒瑞医药股份有限公司 | 一种异喹啉酮类化合物的盐及其晶型 |
| MX2024008959A (es) * | 2022-01-19 | 2024-07-30 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Forma cristalina de derivado de isoindolina que contiene azufre. |
| WO2024167423A1 (en) | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2026112386A1 (en) * | 2024-11-22 | 2026-05-28 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compounds and methods of degrading proteins |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011313A1 (en) | 1977-07-09 | 1980-05-28 | LUCAS INDUSTRIES public limited company | Road vehicle electrical systems |
| DE2848746A1 (de) | 1978-11-10 | 1980-05-22 | Wolfgang Arheiliger | Dichtung fuer eine schwellenlose tuere mit drehfluegel |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| AU2477400A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US20060074103A1 (en) | 2004-10-06 | 2006-04-06 | Corte James R | Cyclic beta-amino acid derivatives as factor Xa inhibitors |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| GB0514018D0 (en) | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| KR101062513B1 (ko) | 2006-02-17 | 2011-09-06 | 에프. 호프만-라 로슈 아게 | 5ｈｔ2/ｄ3 조절제로서의 벤조일-피페리딘 유도체 |
| US8022214B2 (en) | 2007-01-24 | 2011-09-20 | Polyera Corporation | Organic semiconductor materials and precursors thereof |
| CA2681633C (en) | 2007-03-20 | 2018-01-09 | Celgene Corporation | 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
| WO2010057087A1 (en) | 2008-11-17 | 2010-05-20 | Plextronics, Inc. | Organic photovoltaic devices comprising substituted endohedral metallofullerenes |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2381777A4 (en) | 2008-12-12 | 2012-08-08 | Ariad Pharma Inc | AZAINDOL DERIVATIVES AS KINASEHEMMER |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US20130022629A1 (en) | 2010-01-04 | 2013-01-24 | Sharpe Arlene H | Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| WO2011146401A1 (en) | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US9163087B2 (en) | 2010-06-18 | 2015-10-20 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| EP2616469B1 (en) | 2010-09-14 | 2016-10-26 | Exelixis, Inc. | 9h-purine compounds as pi3k-delta inhibitors and methods for their manufacture |
| JP5728921B2 (ja) | 2010-12-10 | 2015-06-03 | コニカミノルタ株式会社 | 光学フィルム、及びそれを用いた偏光板、液晶表示装置 |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| AR092348A1 (es) | 2012-07-11 | 2015-04-15 | Hoffmann La Roche | DERIVADOS DE ARIL-SULTAMO COMO MODULADORES DE RORc |
| UA116544C2 (uk) | 2012-08-09 | 2018-04-10 | Селджин Корпорейшн | Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону |
| WO2014039421A1 (en) | 2012-09-04 | 2014-03-13 | Celgene Corporation | Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof |
| US9695145B2 (en) | 2013-01-22 | 2017-07-04 | Celgene Corporation | Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EP3623011B1 (en) | 2013-08-22 | 2025-02-12 | Vanda Pharmaceuticals Inc. | Trichostatin a for use in multiple myeloma treatment |
| CA2955919A1 (en) | 2014-07-25 | 2016-01-28 | Piramal Enterprises Limited | Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof |
| WO2016019386A1 (en) | 2014-08-01 | 2016-02-04 | Green Revolution Cooling, Inc. | Controller for oil-cooled rack with multiple modes of operation |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| WO2017005900A1 (en) | 2015-07-08 | 2017-01-12 | F. Hoffmann-La Roche Ag | ARYL SULTAM DERIVATIVES AS RORc MODULATORS |
| WO2017161028A1 (en) | 2016-03-16 | 2017-09-21 | Kura Oncology, Inc. | Substituted inhibitors of menin-mll and methods of use |
| AU2017246452C1 (en) | 2016-04-06 | 2021-06-03 | The Regents Of The University Of Michigan | MDM2 protein degraders |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| US20190054097A1 (en) | 2016-04-21 | 2019-02-21 | Bioventures, Llc | Compositions targeting senescent cells and the uses thereof |
| CA3035105C (en) | 2016-08-30 | 2023-09-12 | Dow Global Technologies Llc | Method of attenuating concentration of acrolein |
| CN110049780A (zh) | 2016-10-10 | 2019-07-23 | 塞勒兰特治疗公司 | 异喹啉并苯并二氮杂卓(iqb)-1(氯甲基)-2,3-二氢-1h-苯并[e]吲哚(cbi)二聚体 |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| CN109983027A (zh) | 2016-10-20 | 2019-07-05 | 细胞基因公司 | 基于cereblon的可异二聚化嵌合抗原受体 |
| CA3045037A1 (en) | 2016-12-08 | 2018-06-14 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating cdk4/6-mediated cancer |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| JP7258009B2 (ja) * | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| WO2019114770A1 (zh) | 2017-12-13 | 2019-06-20 | 上海科技大学 | Alk蛋白降解剂及其抗肿瘤应用 |
| PL3796912T3 (pl) * | 2018-05-23 | 2023-09-11 | Celgene Corporation | Związki przeciwproliferacyjne i przeciwciało bispecyficzne przeciwko bcma i cd3 do zastosowania kombinowanego |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
| CN108794453A (zh) | 2018-07-05 | 2018-11-13 | 清华大学 | 一种靶向降解fak蛋白的化合物及其应用 |
-
2018
- 2018-07-09 JP JP2020500862A patent/JP7258009B2/ja active Active
- 2018-07-09 IL IL271889A patent/IL271889B2/en unknown
- 2018-07-09 AU AU2018301335A patent/AU2018301335B2/en active Active
- 2018-07-09 HR HRP20260520TT patent/HRP20260520T1/hr unknown
- 2018-07-09 RS RS20241263A patent/RS66162B1/sr unknown
- 2018-07-09 ES ES24192984T patent/ES3067922T3/es active Active
- 2018-07-09 LT LTEPPCT/US2018/041230T patent/LT3651766T/lt unknown
- 2018-07-09 KR KR1020207003734A patent/KR102656934B1/ko active Active
- 2018-07-09 CN CN201880045745.6A patent/CN110869021B/zh active Active
- 2018-07-09 US US16/030,695 patent/US10357489B2/en active Active
- 2018-07-09 EP EP24192984.3A patent/EP4467143B1/en active Active
- 2018-07-09 SM SM20240470T patent/SMT202400470T1/it unknown
- 2018-07-09 TW TW107123698A patent/TWI791552B/zh active
- 2018-07-09 HU HUE18746444A patent/HUE069137T2/hu unknown
- 2018-07-09 SG SG11202000143PA patent/SG11202000143PA/en unknown
- 2018-07-09 PT PT187464441T patent/PT3651766T/pt unknown
- 2018-07-09 PL PL18746444.1T patent/PL3651766T3/pl unknown
- 2018-07-09 SI SI201831174T patent/SI3651766T1/sl unknown
- 2018-07-09 FI FIEP18746444.1T patent/FI3651766T3/fi active
- 2018-07-09 WO PCT/US2018/041230 patent/WO2019014100A1/en not_active Ceased
- 2018-07-09 TW TW112101268A patent/TWI830576B/zh active
- 2018-07-09 RS RS20260641A patent/RS68146B1/sr unknown
- 2018-07-09 HR HRP20241553TT patent/HRP20241553T1/hr unknown
- 2018-07-09 DK DK18746444.1T patent/DK3651766T3/da active
- 2018-07-09 EP EP26161607.2A patent/EP4768083A2/en active Pending
- 2018-07-09 ES ES18746444T patent/ES2992913T3/es active Active
- 2018-07-09 CA CA3069138A patent/CA3069138A1/en active Pending
- 2018-07-09 SM SM20260239T patent/SMT202600239T1/it unknown
- 2018-07-09 EP EP18746444.1A patent/EP3651766B1/en active Active
-
2019
- 2019-06-03 US US16/430,189 patent/US10675281B2/en active Active
-
2020
- 2020-01-08 EC ECSENADI20201149A patent/ECSP20001149A/es unknown
- 2020-01-08 SA SA520411007A patent/SA520411007B1/ar unknown
- 2020-01-09 ZA ZA2020/00157A patent/ZA202000157B/en unknown
- 2020-01-09 CL CL2020000060A patent/CL2020000060A1/es unknown
- 2020-01-09 CO CONC2020/0000193A patent/CO2020000193A2/es unknown
- 2020-01-10 MX MX2023000085A patent/MX2023000085A/es unknown
- 2020-04-27 US US16/859,357 patent/US11185543B2/en active Active
-
2021
- 2021-11-08 US US17/521,432 patent/US12029738B2/en active Active
-
2022
- 2022-12-13 AU AU2022287569A patent/AU2022287569B2/en active Active
-
2024
- 2024-01-23 US US18/419,894 patent/US20240207255A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI765451B (zh) | 作為erk抑制劑的螺環類化合物及其應用 | |
| KR20210049858A (ko) | Jak 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리딘 화합물 및 이의 용도 | |
| JP2010529088A5 (enExample) | ||
| JP2009531404A5 (enExample) | ||
| SA08290475B1 (ar) | (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه | |
| HRP20241553T1 (hr) | 4-(4-(4-(((2-(2,6-dioksopiperidin-3-il)-l-oksoizoindolin-4-il)oksi)metil)benzil)piperazin-l-il)-3-fluorobenzonitril kao antiproliferativni spoj | |
| JP2020515611A (ja) | 疼痛の処置のための１１，１３−修飾サキシトキシン | |
| PT2070922E (pt) | Derivados de azabiciclo(3.1.0)hexano úteis como moduladores dos receptores d3 da dopamina | |
| MX2015001892A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| BR112015032071B1 (pt) | Modulares do transporte nuclear e suas utilizações | |
| MXPA04003007A (es) | Compuestos azabiciclico sustituidos condensados con heteroarilo para el tratamiento de enfermedades. | |
| UA81186C2 (en) | N-heterocyclylmethyl benzamide derivatives, preparation thereof and use in therapy | |
| CA3100694A1 (en) | Vmat2 inhibitor compounds, compositions, and methods relating thereto | |
| JP2019070057A (ja) | 抗ウイルス化合物の固体形態 | |
| BR112013000783B1 (pt) | Derivados arilamídicos apresentando propriedades antiandrogênicas, seu processo de preparação, e composição farmacêutica | |
| CN101754958A (zh) | 制备高纯度的2,4′-二甲基-3-哌啶-苯丙酮(托哌酮)的方法,包含其的药物组合物以及包含托哌酮的活性物质配制剂 | |
| BRPI0807604A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar, prevenir ou controlar deprressão, dor, ansiedade, e incontiência | |
| CA2931051A1 (en) | Piperidine derivatives having multimodal activity against pain | |
| CA2526989A1 (en) | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors | |
| WO2024059205A1 (en) | Treating pku with spiro-substituted and other piperidine inhibitors of slc6a19 function | |
| CN117551102A (zh) | 替比培南匹伏酯结晶形式、包含其的组合物、制造方法和使用方法 | |
| JP2016540786A5 (enExample) | ||
| WO2016079669A1 (en) | Labeled amino pyrimidine derivatives | |
| TW200811100A (en) | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners | |
| TW201136922A (en) | New oxadiazole derivatives |